Table 3.
Univariate and multivariate analyses for factors associated with HIV-RNA >400 copies/mL after 12 months of cART (N=501)
| Univariate | Multivariate | |||
|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | |
| Age <18 months of age | 1 | … | ||
| 18–59 months of age | 0.9 (0.4 – 2.1) | 0.833 | ||
| 60–155 months of age | 0.7 (0.4 – 1.6) | 0.446 | ||
| ≥156 months of age | 0.8 (0.2 – 2.7) | 0.705 | ||
| Male | 1.9 (1.3 – 2.9) | 0.002 | 1.9 (1.2 – 2.9) | 0.008 |
| Infant ARV for PMTCT | 0.9 (0.5 – 1.8) | 0.753 | ||
| Maternal ARV for PMTCT | 0.6 (0.3 – 1.3) | 0.214 | ||
| History of mono/dual ART | 4.5 (2.7 – 7.8) | <0.001 | 5.7 (3.2 – 10.4) | <0.001 |
| Initial cART regimen NVP-based | 1.6 (1.1–2.5) | 0.026 | 2 (1.2–3.2) | 0.005 |
| Single orphan | 1.7 (1.1 – 2.8) | 0.017 | ||
| Double orphan | 1.4 (0.8 – 2.3) | 0.272 | ||
| Weight for age z score1, per 5 unit | 1.9 (0.7 – 4.8) | 0.184 | ||
| Height for age z score, per 5 unit | 1.3 (0.5 – 3.0) | 0.571 | ||
| Baseline BMI, per 5 unit | 1.5 (0.9 – 2.4) | 0.103 | ||
| WHO Stage I | 1 | … | ||
| Stage II | 0.5 (0.2 – 1.3) | 0.168 | ||
| Stage III | 0.7 (0.3 – 1.9) | 0.545 | ||
| Stage IV | 0.7 (0.3 – 1.9) | 0.518 | ||
| CD4%, per 10% increase | 1.1 (0.8 – 1.4) | 0.659 | ||
| HIV RNA ≥400 copies/ml | 1.7 (0.2 – 14.4) | 0.624 | ||
Abbreviations: OR-odds ratio; CI-confidence interval; ARV-antiretroviral; cART-combination antiretroviral therapy; PMTCT-prevention of mother-to-child transmission; BMI-body mass index.